Astrana Health, Inc. (NASDAQ:ASTH – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the nine brokerages that are presently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $49.4286.
A number of research firms have issued reports on ASTH. Weiss Ratings reissued a “hold (c)” rating on shares of Astrana Health in a report on Thursday, August 27th. Truist Financial boosted their price target on Astrana Health from $47.00 to $55.00 and gave the company a “buy” rating in a research note on Monday, August 10th. BTIG Research increased their price target on Astrana Health from $50.00 to $65.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. Barclays lifted their price objective on Astrana Health from $50.00 to $53.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Finally, TD Cowen upped their target price on Astrana Health from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, July 14th.
Get Our Latest Stock Analysis on ASTH
Astrana Health Stock Down 0.1%
Astrana Health (NASDAQ:ASTH – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.80 EPS for the quarter, beating the consensus estimate of $0.34 by $0.46. Astrana Health had a net margin of 1.05% and a return on equity of 10.30%. The business had revenue of $972.52 million for the quarter, compared to the consensus estimate of $985.62 million. During the same period in the prior year, the company posted $0.19 earnings per share. Astrana Health’s revenue was up 48.5% compared to the same quarter last year. On average, equities analysts expect that Astrana Health will post 1.32 EPS for the current year.
Institutional Investors Weigh In On Astrana Health
Several institutional investors and hedge funds have recently bought and sold shares of the company. Corient Private Wealth LP boosted its position in shares of Astrana Health by 1.6% during the 2nd quarter. Corient Private Wealth LP now owns 24,905 shares of the company’s stock worth $1,156,000 after acquiring an additional 399 shares in the last quarter. Swiss National Bank raised its position in Astrana Health by 1.2% during the third quarter. Swiss National Bank now owns 86,944 shares of the company’s stock valued at $2,465,000 after purchasing an additional 1,000 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new position in Astrana Health during the second quarter valued at approximately $51,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Astrana Health by 5.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,768 shares of the company’s stock worth $799,000 after purchasing an additional 1,263 shares during the last quarter. Finally, Deutsche Bank AG lifted its stake in Astrana Health by 3.9% during the fourth quarter. Deutsche Bank AG now owns 41,265 shares of the company’s stock worth $1,024,000 after purchasing an additional 1,550 shares during the last quarter. Institutional investors own 52.77% of the company’s stock.
About Astrana Health
Astrana Health, Inc is a healthcare management and technology company that helps physicians and healthcare organizations deliver value-based care. The company supports provider groups, independent physicians and health systems with clinical, operational and administrative services designed to coordinate care, improve outcomes and manage healthcare costs.
Astrana Health’s platform includes care-management programs, analytics and population-health tools, technology solutions, physician practice support, and services for risk-bearing provider organizations.
Featured Stories
- Five stocks we like better than Astrana Health
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Receive News & Ratings for Astrana Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrana Health and related companies with MarketBeat.com's FREE daily email newsletter.
